Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2008-01-18 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
股东持股变动公告
Major Shareholding Notification Classification · 100% confidence The document is a shareholder holding change announcement from Wuhan Mayinglong Pharmaceutical Group Co., Ltd. It details the reduction in shares held by a major shareholder, Wuhan State-owned Assets Management Company, including specific share quantities and percentages. The document is short (526 characters) and focuses on changes in significant share ownership levels, which matches the definition of a Major Shareholding Notification. There is no indication of financial statements, management discussion, or other report types. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2008-01-18 Chinese
更正公告
Major Shareholding Notification Classification · 90% confidence The document is a correction announcement regarding a previously published shareholder holding change announcement. It corrects the date range of the shareholding change period. The document is very short (341 characters) and does not contain financial statements or detailed data. It is related to a shareholder holding change, but it is a correction notice rather than the original notification. Given the content and context, it fits best under Major Shareholding Notification (MRQ) as it pertains to shareholder holdings, but since it is a correction to such an announcement, it still falls under MRQ category. Confidence is high due to clear mention of shareholding change and correction.
2008-01-18 Chinese
股价异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock price abnormal fluctuation announcement by Wuhan Mayinglong Pharmaceutical Group Co., Ltd. It discusses the stock price movement over a few days, confirms no undisclosed material information, and references compliance with Shanghai Stock Exchange listing rules. The document is short (597 characters) and serves as a regulatory disclosure about stock price behavior rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is a regulatory announcement related to stock price movement and compliance disclosure, fitting best under Regulatory Filings (RNS).
2008-01-17 Chinese
股东持股变动公告
Major Shareholding Notification Classification · 100% confidence The document is a shareholder shareholding change announcement from Wuhan Mayinglong Pharmaceutical Group Co., Ltd. It details the reduction in shareholding percentages by major shareholders and the updated shareholding structure. There is no indication of financial results, management discussion, or regulatory filings beyond the shareholding change. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2008-01-17 Chinese
2007年度业绩预增公告
Earnings Release Classification · 95% confidence The document is a short announcement (444 characters) about the company's expected performance increase for the fiscal year 2007, including preliminary profit estimates and a statement that the detailed data will be disclosed in the 2007 annual report. It explicitly states that the performance forecast is unaudited and that detailed data will be in the annual report. This is a typical earnings forecast or earnings release type document, not the full annual report itself. Given the short length and nature of the content, it fits best as an Earnings Release (ER) rather than a full Annual Report (10-K) or Report Publication Announcement (RPA). FY 2007
2008-01-07 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Wuhan Mayinglong Pharmaceutical Group Co., Ltd. regarding an external investment in a joint venture company. It details the investment amount, shareholder structure, business scope, governance, and potential impacts and risks of the investment. The document is relatively short (3257 characters) and focuses on the investment transaction rather than financial results or regulatory compliance. It does not contain financial statements or detailed financial analysis. This type of document fits the category of Capital/Financing Update (CAP), as it reports on a new investment and capital allocation by the company.
2007-12-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.